GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors

Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variety of cancer types have paved the way for new immune therapy trials in brain tumor patients. However, the molecular mechanisms that regulate expression of the PD-1 pathway ligands, PD-L1 and PD-L2, remai...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Fu, Yujie, Liu, Connor J., Kobayashi, Dale K., Johanns, Tanner M., Bowman-Kirigin, Jay A., Schaettler, Maximilian O., Mao, Diane D., Bender, Diane, Kelley, Diane G., Uppaluri, Ravindra, Bi, Wenya Linda, Dunn, Ian F., Tao, Yu, Luo, Jingqin, Kim, Albert H., Dunn, Gavin P.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7271235/
https://ncbi.nlm.nih.gov/pubmed/32493985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-65915-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires